Breaking News
FLASH SALE 0
🔎 FLASH SALE: 50% off InvestingPro | See what others miss, trade with confidence.
Claim Sale
Close

Senzime AB (SEZI)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
5.1400 +0.2550    +5.22%
18/06 - Closed. Currency in SEK
Type:  Equity
Market:  Sweden
ISIN:  SE0002478776 
S/N:  156515046
  • Volume: 408,773
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 4.8850 - 5.3100
Senzime 5.1400 +0.2550 +5.22%

Senzime Company Profile

 
Explore the Senzime company profile for core details about Senzime, assess Senzime company details, including a description of the company, key contact information, and insights into the top executives. Discover the company's operations and leadership to better understand its role in the industry.
IndustryHealthcare Equipment & Supplies
SectorHealthcare
Employees

52

Equity Type

ORD

Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. It provides TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue’s opposition to carrying an alternating electrical current. The company has a strategic connectivity and licensing agreement with Masimo to develop, manufacture, market, and distribute products that can connect to the Masimo Root patient monitoring system and related digital hub for data transmission to hospital electronic patient journals; license agreement with Fukuda Denshi Co. Ltd. to license TetraGraph technology; and license agreement with CoreSpiron (Henan) Co Ltd. to manufacture and sell ExSpiron system. Senzime AB (publ) was incorporated in 1999 and is headquartered in Uppsala, Sweden.

Contact Information

Address Vaksalagatan 6
Uppsala, 756 51
Sweden
Phone 46 18 51 56 40
Fax -

Top Executives

Name Age Since Title
Lars Axelson 62 2023 Director
Per Wold Olsen - 2023 Chairman of the Board of Director
Adam Dahlberg 52 2000 Vice Chairman of the Board
Sorin J. Brull 69 2016 Chief Medical Officer, Member of Clinical & Scientific Advisory Board and Director
Per Wold-Olsen 78 2023 Chairman of the Board
Patty Reilly - - Member of Clinical Advisory Board
Guy Cammu - - Member of Scientific Advisory Board
Jennifer Herzog-Niescery - - Member of Clinical Advisory Board
Manfred Blobner - - Member of Scientific Advisory Board
Shane Angus - - Member of Clinical Advisory Board
Claude Meistelman - - Member of Scientific Advisory Board
Thomas Weber - - Member of Clinical Advisory Board
Jennifer M. Hunter - - Member of Scientific Advisory Board
Lars I. Eriksson 68 - Member of Scientific Advisory Board
Cynthia A. Lien - 2022 Member of Scientific Advisory Board
Wolfgang Reim 69 2024 Senior Advisor
Hans D.de Boer - - Member of Scientific Advisory Board
Thomas Fuchs-Buder - - Member of Scientific Advisory Board
Malin Fagerlund - - Member of Clinical Advisory Board
Aaron F. Kopman - 2022 Member of Scientific Advisory Board
Ken B. Johnson - - Member of Clinical Advisory Board
J. Ross Renew - 2022 Member of Scientific Advisory Board
Goran Brorsson 73 2023 Independent Director
Joseph D. Tobias - 2022 Member of Scientific Advisory Board
Alfredo Abad-Gurumeta - - Member of Scientific Advisory Board
Ann Costello 65 2025 Director
Bela Fulesdi - - Member of Scientific Advisory Board
Casper Claudius - - Member of Scientific Advisory Board
Glenn S. Murphy - 2022 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SEZI Comments

Write your thoughts about Senzime AB
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email